Bio-Techne Corporation — Form 10-Q Summary
Reporting period: Unaudited fiscal first quarter ended September 30, 2022 (fiscal 2023 Q1), compared with the quarter ended September 30, 2021. The filing metadata’s “2022 Q1” label differs from the fiscal period stated in the filing.
Financial performance
| Metric | Q1 FY2023 | Q1 FY2022 | Change |
|---|---|---|---|
| Net sales | $269.7 million | $257.7 million | +5%; organic growth +7% |
| Gross margin | 66.6% | 66.4% | +0.2 percentage points |
| Operating income | $56.3 million | $63.2 million | -11% |
| Net earnings attributable to Bio-Techne | $89.6 million | $69.6 million | +29% |
| Diluted EPS | $2.21 | $1.69 | +31% |
| Operating cash flow | $56.1 million | $48.4 million | +$7.6 million |
- Revenue growth comprised 7% organic growth and a 1% contribution from acquisitions, partly offset by a 3% adverse foreign-exchange impact.
- Reported earnings included $37.2 million gain on sale of the ChemoCentryx investment and $11.7 million gain on sale of Eminence. Non-GAAP adjusted net earnings were $72.2 million, down from $75.4 million; adjusted diluted EPS was $1.78 versus $1.83.
- Adjusted gross margin was 70.9%, compared with 71.2% in the prior-year quarter.
- Cash and cash equivalents were $165.3 million and short-term available-for-sale investments were $37.8 million at September 30, 2022, totaling $203.1 million. Cash was $172.6 million at June 30, 2022.
- Quarter-end debt was $264.7 million, all reported as long-term debt. The company replaced its prior credit agreement with a $1.0 billion revolving facility, expandable by $400 million subject to conditions, maturing August 1, 2027. Borrowings carry variable rates based on one-month SOFR plus a leverage-based margin.
- Total current assets were $552.0 million and current liabilities $137.6 million. Operating cash flow was $56.1 million; investing cash flow was a $19.7 million outflow and financing cash flow a $31.8 million outflow.
Segments and material changes
- Protein Sciences: Sales of $199.9 million, up 1% reported and 3% organically. Operating margin fell to 43.0% from 45.7%, with foreign exchange, inflation, growth investment timing, and Namocell contributing to pressure. Management cited U.S. consumables growth and EMEA softness.
- Diagnostics and Genomics: Sales of $69.9 million, up 15% reported and 17% organically. Operating margin increased to 12.4% from 12.2%; growth reflected consumables and services across the portfolio.
- On July 1, 2022, Bio-Techne acquired Namocell for $101.2 million net of cash acquired, with contingent consideration of up to $25 million. Purchase-price allocation remained preliminary. Namocell contributed approximately $2.4 million of sales and $0.7 million of operating loss in the quarter.
- On September 1, the company sold Eminence for approximately $17.8 million, recognizing a $11.7 million gain. Eminence had contributed $2.0 million of quarterly revenue before sale.
- SG&A rose 15% to $99.4 million and R&D rose 11% to $23.9 million; management cited Namocell, inflation, and timing of strategic growth investments.
Outlook, risks and unusual items
- Management expects to meet operating, facility expansion, capital investment, and dividend needs for at least the next 12 months using available cash, operating cash generation, and remaining revolving-credit availability. No revenue or earnings guidance is stated in the provided filing text.
- Capital expenditures for the remainder of fiscal 2023 were expected to be approximately $45 million, primarily to expand capacity for anticipated sales growth.
- Excluding discrete items, the company expected a fiscal 2023 effective tax rate of 23%–27%. The quarter’s reported effective rate was 13.5%, including discrete tax benefits; the prior-year rate was negative 2.4%.
- The company recorded $2.2 million of restructuring charges for the planned closure of its Quad facility, expected to be substantially completed in fiscal Q3 2023.
- A material potential future funding commitment is the Wilson Wolf forward contract: the company forecast a possible $231 million first option payment in fiscal 2023 or 2024 if specified thresholds are met, and a potential second payment of approximately $1 billion plus possible additional consideration during fiscal 2026–2028 if further milestones are reached.
- Other notable risks include variable-rate debt, foreign-exchange exposure, investment valuation, acquisition integration, supply-chain and inflation pressures, cybersecurity, and contingent consideration tied to acquisition milestones. Management reported no material change to previously disclosed risk factors and no legal proceedings expected to have a material adverse effect.
- After quarter-end, shareholders approved an increase in authorized common shares; the company announced a four-for-one stock split and a $0.32-per-share cash dividend.
Key investor verification points
- Separate underlying operating performance from the investment and Eminence disposal gains; review the non-GAAP reconciliations and adjustments.
- Track segment growth and margins, especially the contrast between Diagnostics and Genomics growth and Protein Sciences margin compression.
- Review integration and purchase accounting for Namocell, including the final allocation and contingent-payment exposure.
- Monitor SOFR-linked debt, covenant headroom, facility availability, and the timing and conditions of any Wilson Wolf payments.
- Assess whether planned capacity spending, restructuring, and ongoing inflation and foreign-exchange effects influence future margins and cash generation.
- Confirm subsequent-event details for the stock split and dividend against the company’s related announcements and filings.